118 related articles for article (PubMed ID: 30468974)
1. Novel therapeutics in the treatment of hairy cell leukemia variant.
Letendre P; Doll D
Leuk Res; 2018 Dec; 75():58-60. PubMed ID: 30468974
[No Abstract] [Full Text] [Related]
2. Combo Therapy Effective for Relapsed CLL.
Cancer Discov; 2015 Jul; 5(7):OF8. PubMed ID: 26034053
[No Abstract] [Full Text] [Related]
3. Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.
Imoto N; Koyama D; Sugiura I; Kurahashi S
Medicine (Baltimore); 2021 Feb; 100(5):e24457. PubMed ID: 33592897
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
[TBL] [Abstract][Full Text] [Related]
7. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
Eren R; Suyanı E
Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
[No Abstract] [Full Text] [Related]
8. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Singh M; Mealing S; Baculea S; Cote S; Whelan J
J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for relapsed refractory hairy cell leukemia variant.
Bohn JP; Wanner D; Steurer M
Leuk Lymphoma; 2017 May; 58(5):1224-1226. PubMed ID: 27733095
[No Abstract] [Full Text] [Related]
10. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Molica S
Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India.
Lad DP; Tejaswi V; Malhotra P; Varma N; Sachdeva MS; Naseem S; Sreedharanunni S; Prakash G; Khadwal A; Varma S
Blood Adv; 2018 Nov; 2(Suppl 1):33-34. PubMed ID: 30504196
[No Abstract] [Full Text] [Related]
12. Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Tam CS; Trotman J; Opat S; Stern JC; Allewelt H; By K; Novotny W; Huang J; Tedeschi A
Blood Adv; 2023 Jun; 7(12):2884-2887. PubMed ID: 36753605
[No Abstract] [Full Text] [Related]
13. [Efficacy of rituximab in hairy cell leukemia].
Malfuson JV; Doghmi K; Fagot T; Souleau B; De Revel T; Nedellec G
Presse Med; 2006 May; 35(5 Pt 1):801-2. PubMed ID: 16710151
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
15. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment of refractory hairy cell leukemia with rituximab].
Onaka T; Ozumi N; Yonezawa A; Imada K
Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1987-9. PubMed ID: 19764485
[No Abstract] [Full Text] [Related]
17. Efficacy of rituximab in hairy cell leukemia treatment.
Zinzani PL; Ascani S; Piccaluga PP; Bendandi M; Pileri S; Tura S
J Clin Oncol; 2000 Nov; 18(22):3875-7. PubMed ID: 11078503
[No Abstract] [Full Text] [Related]
18. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
19. Response of hairy cell leukemia to bendamustine.
Kreitman RJ; Arons E; Stetler-Stevenson M; Miller KB
Leuk Lymphoma; 2011 Jun; 52(6):1153-6. PubMed ID: 21463128
[No Abstract] [Full Text] [Related]
20. Successful treatment of hairy cell leukemia variant with rituximab.
Narat S; Gandla J; Dogan A; Mehta A
Leuk Lymphoma; 2005 Aug; 46(8):1229-32. PubMed ID: 16085567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
